Current (as posible)News

Here are some tips for dealing with PSP on a daily basis

1. Medical Management
Medication- Consult with your neurologist about medications that might help manage symptoms, such as those to address stiffness, mood disorders, or other specific issues.
Regular Check-Ups: Maintain regular appointments with your healthcare team to monitor the progression of the disease and adjust treatment plans as necessary.

2. Physical Therapy: Work with a physical therapist to improve balance, mobility, and strength. They can also teach you exercises to maintain flexibility and reduce the risk of falls.
Occupational Therapy: An occupational therapist can help you with strategies to manage daily activities, suggest adaptive equipment, and modify your home environment to make it safer and more accessible.

3. Speech and Swallowing Therapy
Speech Therapy: Speech therapists can assist with communication difficulties by teaching you techniques to improve speech clarity or explore alternative communication methods if necessary.
Swallowing Therapy: They can also help with dysphagia (difficulty swallowing) by recommending exercises and dietary modifications to reduce the risk of choking and aspiration.

4. Assistive Devices and Home Modifications
Mobility Aids: Use canes, walkers, or wheelchairs to enhance mobility and prevent falls.
Home Safety: Make modifications to your home, such as installing grab bars, using non-slip mats, and ensuring good lighting to create a safer living environment.

5. Nutritional Management
Dietary Adjustments: Consult with a dietitian to ensure you are getting adequate nutrition, especially if swallowing becomes difficult. They can recommend food textures and consistencies that are easier to swallow.
Hydration: Maintain proper hydration, which is crucial for overall health and can help with swallowing difficulties.

6. Emotional and Mental Health Support
Counseling: Seek psychological counseling or support groups for emotional support. Coping with a chronic illness can be challenging, and having someone to talk to can make a significant difference.
Support Groups: Join support groups for PSP patients and their families. Sharing experiences and advice with others who understand can provide comfort and practical tips.

7. Daily Routine and Activity Management
Structured Routine: Establish a structured daily routine to provide a sense of normalcy and control.
Pacing Activities: Pace yourself and rest frequently to avoid fatigue. Break tasks into smaller, manageable steps.
Engagement in Activities: Engage in activities that you enjoy and can manage, such as reading, listening to music, or gentle gardening.

8. Caregiver Support
Training and Education: Educate caregivers about PSP and train them in assisting with daily activities, mobility, and emergency procedures.
Respite Care: Arrange for respite care to give primary caregivers a break and prevent burnout.

9. Technological Assistance
Communication Aids: Utilize technology, such as speech-generating devices or communication apps, to help with communication if speech becomes difficult.
Health Monitoring: Use health monitoring devices to track symptoms and manage medication schedules.

10. Legal and Financial Planning
Advance Directives: Prepare advance directives to outline your wishes for medical care.
Financial Planning: Consult with a financial advisor to manage the costs associated with long-term care and to plan for the future.

Managing PSP requires a multidisciplinary approach and the support of healthcare professionals, family, and friends. While there is no cure for PSP, these strategies can help improve daily living and enhance quality of life.

Promising Targets Discovered for Rare Brain Disorder PSP

Summary: Researchers have identified new therapeutic targets for progressive supranuclear palsy (PSP), an incurable brain disorder with symptoms mimicking Parkinson’s and dementia.

The study focused on RNA sequencing from brain samples of over 400 individuals. By analyzing almost 5,000 genes linked with PSP, the team prioritized 11 high-confidence genes.

Reducing levels of DDR2, KANK2, and STOM showed significant promise in reversing the disease.

Key Facts:

  1. Progressive supranuclear palsy (PSP) is an incurable brain disorder that leads to rapid decline and death.
  2. Using RNA sequencing from more than 400 brain samples, researchers identified nearly 5,000 genes associated with PSP.
  3. Among the high-confidence genes, reducing levels of DDR2, KANK2, and STOM presented potential for therapeutic development.

Source: Mayo Clinic

There is no cure for progressive supranuclear palsy (PSP), a brain disorder marked by walking and balance difficulties. Its symptoms also mimic Parkinson’s disease and dementia. The condition leads to rapid, progressive decline and death.

In a new paper published in Nature Communications, Mayo researchers and collaborators outline new therapeutic targets that may lead to potential future treatments for PSP, as well as Alzheimer’s disease and related disorders.

The next steps in this research are to work on the synthesis of small nucleic acid molecules that can regulate the target genes identified in this study. Credit: Neuroscience News

People with PSP usually are diagnosed in their late 60s and 70s. While the cause isn’t known, researchers have found that the deteriorating brain cells of people with PSP have excess amounts of a protein called tau. Clumps of tau are also found in people with other neurodegenerative disorders, such as Alzheimer’s disease.

In this study, the researchers zeroed in on RNA, the carrier of genetic information in all living cells.

They integrated brain RNA data from two large, independent human study groups, including donor samples from patients with PSP from the Mayo Clinic Brain Bank. They performed RNA sequencing, which allowed them to discover which genes in certain brain cells were abnormally high or low in patients with PSP.

Each study group contained brain samples from people who had died from PSP, as well as a control group of brain samples from people who did not die from a neurodegenerative disorder. The researchers used samples from more than 400 people overall.


After performing the RNA sequencing, the researchers used a computational model to systematically identify nearly 5,000 genes involved in PSP in relevant brain cells. They then compared their findings to an analysis performed in a preclinical model that mimics the brain pathology seen in PSP.

In the end, the researchers “ranked,” or prioritized, 11 high-confidence genes that are unusually elevated in human PSP brains and this model.

Finally, the investigators manipulated these target genes in an experimental fruit fly model. They wanted to determine whether reducing the levels of these abnormally elevated genes could correct the degeneration in the model.

Among the 11 high-confidence genes, researchers found that reducing the levels of DDR2, KANK2 and STOM showed the most promise in reversing disease and as leading targets for therapeutic development.

“This research enhances our understanding of progressive supranuclear palsy and other related incurable neurological disorders,” says the study’s senior author, Nilüfer Ertekin-Taner, M.D., Ph.D., a Mayo Clinic neurologist, neuroscientist and chair of the Department of Neuroscience.

“Moving forward, we can target these specific genes or others that are biologically related to them to develop a potential treatment for this untreatable disease.”

The team also built a web application to enable data-sharing among the wider research community.

“This project highlights the power of multiomics data,” says Yuhao (Harry) Min, a Mayo Clinic Graduate School of Biomedical Sciences predoctoral student in the Clinical and Translational Science track and first author of the paper.


“Using these datasets, we were able to tease apart the complex molecular changes that took place in patients with PSP, which is important to understand to find a cure for this disorder.

“We also shared our datasets with the scientific community to enable collaborative efforts, with the goal of finding a treatment for patients. Because PSP shares similar biology as other neurological disorders such as Alzheimer’s disease, we hope our findings might also benefit drug discovery efforts in other neurological disorders.”

The next steps in this research are to work on the synthesis of small nucleic acid molecules that can regulate the target genes identified in this study. The researchers hope to assess the safety and efficacy of those molecules in cell and animal models, with the long-term goal of beginning clinical trials in PSP patients.

About this PSP and neurology news

Author: Lynda De Widt
Source: Mayo Clinic
Contact: Lynda De Widt – Mayo Clinic
Image: The image is credited to Neuroscience News

Original Research: Open access.
Cross species systems biology discovers glial DDR2, STOM, and KANK2 as therapeutic targets in progressive supranuclear palsy” by Nilüfer Ertekin-Taner et al. Nature Communication



Cross species systems biology discovers glial DDR2, STOM, and KANK2 as therapeutic targets in progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by cell-type-specific tau lesions in neurons and glia. Prior work uncovered transcriptome changes in human PSP brains, although their cell-specificity is unknown. Further, systematic data integration and experimental validation platforms to prioritize brain transcriptional perturbations as therapeutic targets in PSP are currently lacking.

In this study, we combine bulk tissue (n = 408) and single nucleus RNAseq (n = 34) data from PSP and control brains with transcriptome data from a mouse tauopathy and experimental validations in Drosophila tau models for systematic discovery of high-confidence expression changes in PSP with therapeutic potential. We discover, replicate, and annotate thousands of differentially expressed genes in PSP, many of which reside in glia-enriched co-expression modules and cells.

We prioritize DDR2, STOM, and KANK2 as promising therapeutic targets in PSP with striking cross-species validations. We share our findings and data via our interactive application tool PSP RNAseq Atlas (

Our findings reveal robust glial transcriptome changes in PSP, provide a cross-species systems biology approach, and a tool for therapeutic target discoveries in PSP with potential application in other neurodegenerative disea




C-Path announces formation of new task force to foster drug development for Progressive Supranuclear Palsy

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform, dedicated to advancing therapeutic development for Progressive Supranuclear Palsy.

26 Mar 2024

UVA Alzheimer's study pinpoints how tau protein damages brain cells

University of Virginia Alzheimer's researchers have discovered how harmful tau proteins damage the essential operating instructions for our brain cells, a finding which could lead to new treatments.

20 Dec 2023

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Wearable devices and machine learning revolutionize Parkinson's disease monitoring

The quantitative progression of motor symptoms of Parkinson's disease (PD) over time using wearable sensor data.

11 Oct 2023



Developer launches long-awaited study of light device for Parkinson’s

PhotoPharmics overcomes funding, pandemic challenges to test treatment

by Marisa Wexler, MS | March 28, 2024

After years of delays, medical device company Photopharmics has started a pivotal clinical trial to test its Celeste device, a noninvasive treatment tool that aims to use light to manage the symptoms of Parkinson’s disease.


The long-awaited trial has been in the works since 2020, shortly after the light-based therapy was granted breakthrough device designation by the U.S. Food and Drug Administration (FDA).

“After overcoming funding challenges and delays caused by the global pandemic, we are thrilled to launch this trial, which holds immense promise for those affected by Parkinson’s disease,” Kent Savage, president and CEO of Photopharmics, said in a company press release.

The study is being run as a collaboration between Photopharmics and the Center for Health and Technology at the University of Rochester Medical Center (URMC), in New York. Additional information, including a form patients can use to determine if they’re eligible to participate in the study, is available at the trial’s website,

March 7, 2024 Columns by Jill Hammergren

How a red light and profanity have helped us in life with Parkinson’s

Telemedicine trial approach will assess light device from patients’ homes

The Celeste device was developed based on the finding that Parkinson’s frequently causes damage to cells in the retina, the part of the eye that senses light. The research showed that patients often experience abnormalities in circadian rhythms — the day-by-day biological cycles that help control bodily processes like hunger and sleep.


The device, which is noninvasive, uses light-based therapy, called phototherapy, to activate specific receptors in the eye that help regulate circadian rhythms. In doing so, the light device aims to help ease Parkinson’s symptoms that are associated with circadian rhythm abnormalities, such as sleep problems, fatigue, and depression.

Dan Adams, Photopharmics’ chief science officer, said the device “demonstrated remarkable improvements in both quality of life and non-motor symptoms for [Parkinson’s] patients” in early clinical studies.


Adams added that Celeste promises to be “a new horizon in [Parkinson’s] treatment.”

According to Adams, a pivotal trial for a medical device is similar to a Phase 3 clinical trial for a medication — it’s a large study designed to test the effectiveness of the treatment. He said that Photopharmics has already presented the trial’s design to the FDA, which gave it a “favorable review.”

The trial’s design was to be shared with scientists and medical professionals last year at the World Parkinson Congress, which the company hoped would allow for collaboration with researchers